North America CAR T-Cell Therapy Market (2026-2031)
The North America CAR T-Cell Therapy Market was valued at $273.4 Million in 2026 and projected to reach to $510.2 Million by 2031, representing a compound annual growth rate of 13.3%. North America's CAR T-cell therapy market is poised for sustained expansion through 2031, driven by broadening clinical indications beyond hematologic malignancies into solid tumors and earlier treatment lines.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
North America CAR T-Cell Therapy Market Trends and Insights
- North America's leadership is driven by advanced healthcare infrastructure, robust regulatory frameworks, and substantial investment in oncology innovation.
- The region's 13.3% compound annual growth rate reflects strong clinical adoption and increasing patient access to approved CAR T-cell therapies. In North America, the market expansion is supported by a growing pipeline of clinical trials, rising prevalence of hematologic malignancies, and expanding reimbursement coverage.
- North America continues to lead in manufacturing capabilities and commercialization strategies, with major pharmaceutical and biotech companies establishing regional centers of excellence.
- Between 2026 and 2031, North America is expected to maintain its competitive advantage through continued innovation and strategic partnerships in the CAR T-cell therapy space..
Key Market Statistics
- CAGR (2026-2031) 13.3% CAGR
- Market Size, 2026 ~USD 273.4 Million
- Forecast, 2031 ~USD 510.2 Million
- Geography North America
North America CAR T-Cell Therapy Market Overview
Market Leadership Position :
North America commands a dominant position in CAR T-cell therapy adoption, with the US alone representing $441.2 million of the regional market, driven by FDA approvals, early patient access, and established reimbursement pathways.
Robust Growth Trajectory :
The region is experiencing a 13.3% CAGR from 2026 to 2031, expanding from $273.4 million to $510.2 million, reflecting accelerating clinical adoption and increasing patient populations eligible for CAR T-cell treatments.
Advanced Healthcare Infrastructure :
North America benefits from world-class oncology centers, specialized treatment facilities, and integrated healthcare systems that support complex CAR T-cell manufacturing, administration, and patient monitoring protocols.
Regulatory and Investment Momentum :
Strong regulatory frameworks, substantial R&D funding, and competitive pharmaceutical investments position North America as the innovation epicenter for next-generation CAR T-cell therapies and combination treatment approaches.
North America CAR T-Cell Therapy Market Dynamics
- Increasing manufacturing capacity, improved cost structures, and expanding insurance coverage will accelerate market penetration across major US and Canadian healthcare systems.
- The region's leadership in clinical trials and regulatory approvals ensures continued first-mover advantages for emerging therapies. Key growth catalysts include rising lymphoma and leukemia incidence, growing patient awareness, and integration of CAR T-cell therapy into standard-of-care protocols.
- Strategic partnerships between biotech firms and healthcare providers, coupled with investments in manufacturing infrastructure, will enhance accessibility.
- By 2031, North America is expected to maintain its position as the largest regional market, with the US contributing the majority of growth through expanded patient populations and premium pricing dynamics..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- North America's CAR T-cell therapy market is valued at $273.4 million in 2026 and will reach $510.2 million by 2031, representing a 13.3% CAGR.
- North America leads globally in regulatory approval and commercialization of CAR T-cell therapies, supported by FDA-approved treatments and expanding clinical pipelines.
- In North America, rising hematologic malignancy prevalence and improved reimbursement policies are key drivers of market growth through 2031.
- North America's advanced manufacturing infrastructure and strategic partnerships position the region as a center for CAR T-cell therapy innovation and production.
CAR T-Cell Therapy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CD19/20 (Target) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 13.7% from 2026 to 2031 |
| Largest Segment | CD19 (Target) |
| Market Size Base Year (Billions) | ~USD 7.25 (2026) |
| Revenue Forecast (Billions) | ~USD 13.78 (2031) |
| Segments Covered | Product, Target, Indication |
North America CAR T-Cell Therapy Market Report Segmentation
3 segment dimensions are covered across the global market.
By Product
- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Other Products
- Tecartus
- Yescarta
By Target
- Bcma
- Cd19
- Cd19/20
- Cd7
- Other Targets
By Indication
- Acute Lymphoblastic Leukemia (All)
- B-Cell Lymphoma (Bcl)
- Multiple Myeloma
- Other Indications
Target Audience
- Pharmaceutical & Biotech Companies : Manufacturers and developers of CAR T-cell therapies require North America-specific market data to guide clinical development priorities, pricing strategies, and commercial launch planning in this premium market.
- Healthcare Investors & PE Firms : Investment professionals evaluating oncology immunotherapy opportunities need regional market sizing, growth forecasts, and competitive dynamics to assess portfolio companies and identify acquisition targets in North America.
- Hospital Systems & Oncology Centers : Healthcare providers planning CAR T-cell therapy program expansion require market intelligence on patient populations, treatment trends, and reimbursement landscapes to optimize resource allocation and service offerings.
- Medical Device & Manufacturing Suppliers : Suppliers of manufacturing equipment, cell processing systems, and logistics solutions need North American market forecasts to plan capacity investments and identify partnership opportunities with therapy providers.
- Healthcare Consultants & Analysts : Strategy consultants and market analysts supporting healthcare clients require detailed North America CAR T-cell market data to develop competitive strategies, market entry plans, and investment recommendations.
Key Companies in the North America CAR T-Cell Therapy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| JOHNSON & JOHNSON | United States | Public Company | Oncology and Immunology (Innovative Medicine),Neuroscience, Cardiovascular & Metabolism, Pulmonary Hypertension, Infectious Diseases,Surgery and Interventional (instrumentation, energy, stapling, wound closure, biosurgery, robotic and digital), |
| GILEAD SCIENCES, INC. | United States | Public Company | HIV portfolio (Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo),Liver disease and other antivirals (Epclusa, Livdelzi, Vemlidy, AmBisome),COVID-19 (Veklury), |
| BRISTOL-MYERS SQUIBB COMPANY | United States | Public Company | Eliquis (anticoagulation),Immuno-oncology (Opdivo, Yervoy, Opdualag, Opdivo Qvantig),Hematology (Revlimid, Pomalyst/Imnovid, Reblozyl, Abecma, Breyanzi), |
| NOVARTIS AG | Switzerland | Public Company | Oncology & Hematology (Kisqali, Tafinlar+Mekinist, Jakavi, Pluvicto, Lutathera, Scemblix, Fabhalta),Immunology & Neuroscience (Cosentyx, Xolair, Ilaris, neurology assets),Cardiovascular, Renal & Metabolic (Entresto, Leqvio, other CVRM), |
| AUTOLUS THERAPEUTICS | United Kingdom | Public Company | CD19 CAR-T franchise (AUCATZYL / obe-cel – oncology),Autoimmune CD19 programs (obe-cel in SLE, MS, lupus nephritis),Next-generation oncology pipeline (AUTO1/22, AUTO8, AUTO6NG), |
| JW (CAYMAN) THERAPEUTICS CO., LTD. | China | Public Company | Commercial and late-stage CAR-T for hematologic malignancies (Carteyva, JWCAR201, JWCAR239),Autoimmune indications (relma-cel for SLE and related programs),Solid tumor pipeline (JWATM204/214/203/213, JWTCR001, JWCAR031), |
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | China | Public Company | Zevor-cel (CT053) – BCMA CAR-T for R/R multiple myeloma,Autologous solid-tumor CAR-T (CT041, CT011, CT071, CT0590/CT0596),Autoimmune and B-cell malignancy pipeline (KJ-C2219, KJ-C2320, KJ-C2529), |
| CARTESIAN THERAPEUTICS, INC. | United States | Public Company | Descartes-08 (autoimmune and rare pediatric indications),Descartes-15 (multiple myeloma),Platform and other mRNA cell therapy programs/services, |
| LYELL IMMUNOPHARMA, INC. | United States | Public Company | Hematologic CAR T programs (ronde-cel and platform),Solid tumor CAR T programs (LYL273 and related),Platform technologies and enabling IP (c-Jun, NR4A3 KO, Epi-R, CD62L enrichment), |
JOHNSON & JOHNSON
Johnson & Johnson is a diversified healthcare company founded in 1886 and headquartered in the United States. With 138,200 employees, it operates as a public company serving global markets.
GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a United States-based biopharmaceutical company founded in 1987. The public company employs 17,000 people and focuses on developing innovative therapeutics.
BRISTOL-MYERS SQUIBB COMPANY
Bristol-Myers Squibb Company is a pharmaceutical company established in 1887 in the United States. As a public company with 32,500 employees, it develops and manufactures pharmaceutical products.
NOVARTIS AG
Novartis AG is a Swiss multinational pharmaceutical company founded in 1996. The public company employs 75,267 people and operates globally in the healthcare sector.
AUTOLUS THERAPEUTICS
Autolus Therapeutics is a United Kingdom-based biopharmaceutical company founded in 2014. The public company has 753 employees and focuses on cell therapy development.
JW (CAYMAN) THERAPEUTICS CO., LTD.
JW (Cayman) Therapeutics Co., Ltd. is a China-based pharmaceutical company founded in 2016. The public company employs 314 people and operates in the therapeutic development sector.
CARSGEN THERAPEUTICS HOLDINGS LIMITED
Carsgen Therapeutics Holdings Limited is a China-based biopharmaceutical company founded in 2014. The public company has 355 employees and specializes in cell therapy development.
CARTESIAN THERAPEUTICS, INC.
Cartesian Therapeutics, Inc. is a United States-based public biopharmaceutical company with 75 employees. The company specializes in cell therapy and therapeutic development.
LYELL IMMUNOPHARMA, INC.
Lyell Immunopharma, Inc. is a United States-based public immunotherapy company founded in 2018. The company has 161 employees and develops cell-based immunotherapies.
Countries within North America - compare and drill down
| Country | 2025 size (native) |
|---|---|
| US | USD 441.2 Million |
| Canada | USD 697.5 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Quantification : Access precise market sizing and forecasting data specific to North America, including country-level breakdowns for the US and Canada, enabling accurate revenue projections and market opportunity assessments.
- Competitive Landscape Intelligence : Understand North American market dynamics, key players, regulatory approvals, and clinical trial pipelines to identify competitive positioning and partnership opportunities in this high-growth region.
- Investment Decision Support : Leverage detailed growth forecasts, CAGR analysis, and market drivers specific to North America to support capital allocation decisions, M&A strategies, and market entry planning.
- Regulatory and Reimbursement Insights : Gain actionable intelligence on FDA approval pathways, insurance coverage policies, and healthcare system adoption patterns unique to North American markets to optimize commercialization strategies.
- Strategic Market Positioning : Identify emerging opportunities in underserved patient populations, geographic gaps, and therapeutic indications within North America to guide product development and go-to-market initiatives.
Frequently asked questions
What is the current market size of CAR T-cell therapy in North America?
North America's CAR T-cell therapy market is estimated at $273.4 million in 2026 and is projected to grow to $510.2 million by 2031.
What is the growth rate for CAR T-cell therapy in North America?
North America's CAR T-cell therapy market is expected to grow at a compound annual growth rate (CAGR) of 13.3% from 2026 to 2031.
What factors are driving CAR T-cell therapy adoption in North America?
North America's market growth is driven by FDA approvals, expanding clinical pipelines, rising hematologic malignancy prevalence, improved reimbursement policies, and advanced healthcare infrastructure.
Which countries in North America are leading CAR T-cell therapy adoption?
The United States dominates North America's CAR T-cell therapy market due to its advanced regulatory framework, robust healthcare system, and significant investment in oncology research and development.
How does North America's CAR T-cell therapy market compare to other regions?
North America leads globally in CAR T-cell therapy adoption, regulatory approvals, and commercialization, supported by its advanced healthcare infrastructure and strong pharmaceutical innovation ecosystem.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
CAR T-Cell Therapy Market Size: Bottom-up Approach and Top-down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CAR T-cell therapy is a treatment method wherein a patient’s T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient’s bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is known as a chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapeutic purposes.
Key Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations (CROs)
- Regulatory Authorities
- Healthcare Providers
- Patients and Patient Advocacy Groups
- Investors and Venture Capital Firms
- Research & Development Companies
- Research Laboratories & Academic Institutes.
- Market Research & Consulting Firms
Report Objectives
- To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
- To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at the global level
- To provide detailed information regarding the major drivers, restraints, opportunities, and challenges, influencing the market growth
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
- To provide an overview of the market with specialized analysis such as trends/disruptions impacting customers’ business, pricing analysis, value/ supply chain analysis,ecosystem analysis, technology analysis, patent analysis, key conferences & events 2026-2027, regulatory landscape, Porter’s five forces analysis, key stakeholders and buying criteria, and investment and funding scenario
Available customizations:
- With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe CAR T-cell therapy market, by country
- Further breakdown of the Rest of Asia Pacific CAR T-cell therapy market, by count
Company Information
- Detailed analysis and profiling of additional market players (up to five
Segment Analysis
- Cross-segment analysis
Get the Full CAR T-Cell Therapy Market Report
Full forecast, segment splits, and company analysis for all CAR T-Cell Therapy Market.
- US CAR T-Cell Therapy Market
- Canada CAR T-Cell Therapy Market
- Germany CAR T-Cell Therapy Market
- UK CAR T-Cell Therapy Market
- France CAR T-Cell Therapy Market
- Italy CAR T-Cell Therapy Market
- Spain CAR T-Cell Therapy Market
- China CAR T-Cell Therapy Market
- Japan CAR T-Cell Therapy Market
- India CAR T-Cell Therapy Market
- Australia CAR T-Cell Therapy Market
- South Korea CAR T-Cell Therapy Market
- Brazil CAR T-Cell Therapy Market
- UAE CAR T-Cell Therapy Market
- Rest Of Europe CAR T-Cell Therapy Market
- Rest Of Asia Pacific CAR T-Cell Therapy Market
- Rest Of Latin America CAR T-Cell Therapy Market
- GCC Countries CAR T-Cell Therapy Market
- Rest Of Middle East CAR T-Cell Therapy Market
- Kingdom Of Saudi Arabia CAR T-Cell Therapy Market
- Rest Of GCC Countries CAR T-Cell Therapy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report